Biohaven Ltd.

BHVN

Biohaven Ltd.

BHVN

Insider Sentiment (TTM):

Last Purchase:2025-11-17Last Sale:2023-12-29Shares Purchased (TTM):4,416,999Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:137,736,606Shares Outstanding:147,615,197Institutional Ownership Pct.:93.31%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	238	273	230	185	166	98	99	84	239	183	248	112
Marketable Securities Current	30	75	89	75	239	224	387	294	198	101	133	129
Prepaid Expense Current	27	35	47	55	61	56	49	55	60	46	35	34
Other Assets Current	2	3	2	8	8	4	3	1	7	11	12	23
Income Taxes Receivable	-	-	-	-	-	-	3	5	8	8	13	13
Restricted Cash Current	-	-	-	-	-	-	-	-	-	-	0	0
Assets Current	297	386	368	324	475	383	538	441	511	349	442	311
Property Plant And Equipment Net	15	15	16	18	19	18	17	18	19	17	17	18
Intangible Assets Net Excluding Goodwill	18	18	18	18	18	18	18	18	18	18	18	18
Goodwill	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	39	46	47	48	37	39	40	32	33	33	34	35
Assets	371	466	451	409	550	459	615	511	583	419	513	383
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	12	10	12	17	20	19	18	20	17	36	16	10
Accrued Liabilities Current	51	42	104	74	79	57	51	64	58	50	40	53
Liabilities Current	63	52	116	113	124	164	154	152	156	87	55	62
Operating Lease Liability Noncurrent	33	38	40	40	30	31	33	25	26	27	28	28
Derivative Liabilities Noncurrent	-	-	-	-	-	-	-	12	12	-	-	-
Long Term Notes Payable	259	242	239	268	257	-	0	-	-	-	-	-
Other Liabilities Noncurrent	3	5	5	5	5	5	5	5	4	3	2	2
Liabilities	359	337	399	426	416	199	192	195	199	117	85	93
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	2,139	2,133	1,934	1,744	1,743	1,689	1,657	1,382	1,299	911	888	619
Additional Paid In Capital	220	203	194	178	157	137	112	93	84	69	40	26
Retained Earnings Accumulated Deficit	-2,352	-2,215	-2,085	-1,939	-1,766	-1,567	-1,346	-1,159	-999	-679	-499	-355
Accumulated Other Comprehensive Income Loss Net Of…	5	8	8	0	-0	0	0	0	-0	-0	-0	0
Stockholders Equity	12	130	52	-17	135	259	423	316	384	301	428	290
Liabilities And Stockholders Equity	371	466	451	409	550	459	615	511	583	419	513	383
Preferred Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock No Par Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	151	151	133	106	106	102	101	95	92	82	81	68
Shares Outstanding	151	151	133	106	106	102	101	95	92	82	81	68

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	8.58%	56.11%	41.22%	-	-	-	-	-	-	-	-	-
2025	-17.17%	-28.84%	-28.45%	18.34%	17.90%	28.26%	22.59%	39.15%	51.86%	-29.13%	-16.34%	-19.98%
2024	-15.14%	-16.08%	-0.36%	1.26%	31.07%	35.80%	-11.04%	-23.27%	-24.05%	-13.76%	-38.12%	-51.22%
2023	-	-	-	-	-	-	11.01%	43.02%	50.40%	16.02%	-19.01%	-22.37%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.73	7.41	3.18	2.86	3.82	2.33	3.49	2.89	3.27	4.03	7.98	4.99
Quick Ratio	4.30	6.74	2.77	2.38	3.32	1.99	3.17	2.53	2.89	3.49	7.35	4.45
Working Capital	233.90M	333.57M	252.40M	210.59M	350.50M	218.72M	384.25M	288.21M	355.06M	262.16M	387.02M	248.39M
Leverage & Debt
Debt to Equity	29.33	2.60	7.67	-24.84	3.09	0.77	0.45	0.62	0.52	0.39	0.20	0.32
Debt Ratio	0.97	0.72	0.88	1.04	0.76	0.43	0.31	0.38	0.34	0.28	0.17	0.24
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-3.90	-4.39	-6.86	-7.37	-7.49	-8.72	-9.28	-8.52	-8.51	-6.34	-5.73	-11.19
Free Cash Flow Per Share TTM	-3.50	-4.03	-5.67	-4.58	-4.70	-6.37	-6.43	-5.63	-5.53	-4.41	-4.70	-4.32
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-23.49%	-27.11%	-12.71%	-3.01%	2.73%	71.82%	107.37%	5.16%	2.12%	-	-	-
EPS Growth (1Y)	-48.00%	-49.66%	-26.01%	-13.50%	-11.93%	37.53%	61.84%	-23.87%	-20.59%	-	-	-
Valuation Metrics
P/E TTM	-3.82	-1.93	-1.64	-2.04	-1.88	-2.76	-4.03	-5.86	-4.08	-8.63	-7.47	-2.32
P/B TTM	183.40	9.64	23.33	-92.56	10.73	9.44	8.05	14.92	7.94	14.80	7.12	6.13
Market Cap	2.24B	1.25B	1.22B	1.59B	1.44B	2.45B	3.41B	4.72B	3.05B	4.46B	3.05B	1.78B
Enterprise Value	2.26B	1.21B	1.22B	1.67B	1.53B	2.35B	3.31B	4.63B	2.80B	4.28B	2.80B	1.65B
Calculated Values
Free Cash Flow TTM	-527.54M	-594.94M	-610.61M	-485.15M	-481.30M	-649.01M	-586.50M	-531.06M	-485.24M	-359.48M	-334.77M	-295.13M
Net Debt	18.85M	-35.19M	6.12M	79.89M	88.07M	-102.69M	-102.54M	-88.02M	-242.32M	-186.93M	-252.12M	-125.99M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-17Purchase

Owner: Clark, George C.

Title: VP, Chief Accounting Officer

Shares: 17,000

Price/Share: $8.52

Value: $144,840.00

Shares Owned: 20,000

Relationship: Officer

Ownership: Indirect

2025-11-13Purchase

Owner: Coric, Vlad

Title: Chief Executive Officer

Shares: 666,666

Price/Share: $7.50

Value: $4,999,995.00

Shares Owned: 1,195,275

Relationship: Director,Officer

Ownership: Indirect

2025-11-13Purchase

Owner: Childs, John W

Title: -

Shares: 3,333,333

Price/Share: $7.50

Value: $24,999,997.50

Shares Owned: 5,653,904

Relationship: Director

Ownership: Indirect

2025-11-13Purchase

Owner: Bailey, Gregory

Title: -

Shares: 400,000

Price/Share: $7.50

Value: $3,000,000.00

Shares Owned: 2,020,071

Relationship: Director

Ownership: Direct

2025-03-04Purchase

Owner: Childs, John W

Title: -

Shares: 28,400

Price/Share: $30.43

Value: $864,212.00

Shares Owned: 2,323,971

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-17	Clark, George C.	Officer	VP, Chief Accounting Officer	Indirect	Purchase	17,000	8.52	$144,840.00	20,000	4
2025-11-13	Coric, Vlad	Director,Officer	Chief Executive Officer	Indirect	Purchase	666,666	7.50	$4,999,995.00	1,195,275	4
2025-11-13	Childs, John W	Director	-	Indirect	Purchase	3,333,333	7.50	$24,999,997.50	5,653,904	4
2025-11-13	Bailey, Gregory	Director	-	Direct	Purchase	400,000	7.50	$3,000,000.00	2,020,071	4
2025-03-04	Childs, John W	Director	-	Indirect	Purchase	28,400	30.43	$864,212.00	2,323,971	4/A
2025-03-04	Childs, John W	Director	-	Indirect	Purchase	32,700	30.64	$1,001,928.00	2,320,571	4
2024-12-30	Childs, John W	Director	-	Indirect	Purchase	29,000	35.94	$1,042,260.00	2,368,741	4
2024-10-02	Coric, Vlad	Director,Officer	Chief Executive Officer	Indirect	Purchase	21,052	47.50	$999,970.00	861,942	4
2024-10-02	Childs, John W	Director	-	Indirect	Purchase	21,052	47.50	$999,970.00	21,052	4
2024-09-24	Bailey, Gregory	Director	-	Direct	Purchase	5,000	44.19	$220,950.00	1,620,071	4
2024-07-18	Childs, John W	Director	-	Indirect	Purchase	28,400	35.67	$1,013,028.00	2,339,741	4
2024-06-17	Car, Bruce	Officer	Chief Scientific Officer	Indirect	Purchase	30,000	33.58	$1,007,400.00	30,000	4
2024-05-30	Childs, John W	Director	-	Indirect	Purchase	28,000	35.58	$996,240.00	2,311,341	4
2024-05-13	Bailey, Gregory	Director	-	Direct	Purchase	15,000	34.19	$512,850.00	1,615,071	4
2024-05-13	Childs, John W	Director	-	Indirect	Purchase	28,500	35.17	$1,002,345.00	2,283,341	4
2024-04-24	Bailey, Gregory	Director	-	Direct	Purchase	25,503	39.18	$999,207.54	1,600,071	4
2024-04-22	Childs, John W	Director	-	Indirect	Purchase	73,170	41.00	$2,999,970.00	73,170	4/A
2024-04-22	Childs, John W	Director	-	Indirect	Purchase	195,121	41.00	$7,999,961.00	4,096,512	4
2024-04-22	Bailey, Gregory	Director	-	Direct	Purchase	48,780	41.00	$1,999,980.00	1,574,568	4
2024-04-22	Coric, Vlad	Director,Officer	Chief Executive Officer	Direct	Purchase	121,951	41.00	$4,999,991.00	1,788,417	4
2023-12-29	Antonijevic, Irina	Director	-	Direct	Sale	11,000	41.79	$459,690.00	2,535	4
2023-10-05	Coric, Vlad	Director,Officer	Chief Executive Officer	Direct	Purchase	113,637	22.00	$2,500,014.00	1,657,031	4
2023-10-05	Buten, Matthew	Officer	Chief Financial Officer	Direct	Purchase	22,727	22.00	$499,994.00	189,380	4
2023-10-05	Childs, John W	Director	-	Indirect	Purchase	454,545	22.00	$9,999,990.00	3,998,952	4
2023-10-04	Bailey, Gregory	Director	-	Direct	Purchase	17,817	22.57	$402,129.69	1,525,788	4
2023-08-30	Childs, John W	Director	-	Indirect	Purchase	50,000	18.44	$922,000.00	1,975,118	4
2023-08-04	Childs, John W	Director	-	Indirect	Purchase	100,000	19.78	$1,978,000.00	1,925,118	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

93.31%

Inst. Shares: 137,736,606

Shares Outstanding: 147,615,197

2025-12-31

107.01%

Inst. Shares: 115,172,838

Shares Outstanding: 107,624,885

2025-09-30

76.93%

Inst. Shares: 81,402,137

Shares Outstanding: 105,815,038

2025-06-30

81.00%

Inst. Shares: 82,923,949

Shares Outstanding: 102,372,820

2025-03-31

83.20%

Inst. Shares: 84,816,818

Shares Outstanding: 101,943,396

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	137,736,606	147,615,197	93.31%
2025-12-31	115,172,838	107,624,885	107.01%
2025-09-30	81,402,137	105,815,038	76.93%
2025-06-30	82,923,949	102,372,820	81.00%
2025-03-31	84,816,818	101,943,396	83.20%
2024-12-31	88,274,152	91,234,337	96.76%
2024-09-30	81,487,556	94,372,159	86.35%
2024-06-30	78,569,835	87,766,069	89.52%
2024-03-31	68,275,479	81,601,826	83.67%
2023-12-31	67,685,706	71,200,527	95.06%
2023-09-30	58,306,677	68,320,125	85.34%
2023-06-30	57,940,535	68,248,023	84.90%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Biohaven Ltd. (BHVN) — SEC Financial Statements & Analysis

Biohaven Ltd. (BHVN) is a pharmaceutical preparations company, incorporated in D8. Biohaven Ltd. trades on NYSE as: BHVN. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Biohaven Ltd. reported a Debt-to-Equity ratio of 29.33x, a Price-to-Book (P/B) ratio of 183.40x (TTM), at a market cap of $2.24B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 29.33x
P/B TTM: 183.40x
Market Cap: $2.24B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Biohaven Ltd. in?

Biohaven Ltd. (BHVN) operates in the Pharmaceutical Preparations industry.

What is BHVN's market cap?

Biohaven Ltd. (BHVN) has a market capitalization of $2.24B as of 2026-06-30.

What exchange does BHVN trade on?

Biohaven Ltd. (BHVN) trades on the NYSE.

Where is Biohaven Ltd. incorporated?

Biohaven Ltd. is incorporated in Virgin Islands, British.

Biohaven Ltd.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Biohaven Ltd. (BHVN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Biohaven Ltd. (BHVN) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.